Brain metastases are a major cause of morbidity and mortality in patients with non-small cell lung carcinomas. However, effective therapies have not yet been developed. Targeted therapies based on driver genetic alterations are becoming standard treatment for patients with non-small cell lung carcinomas. Thus, effective therapy for brain metastases should be established based on the elucidation of critical genetic events related to metastases. Epidermal growth factor receptor or HER2 deregulation has been observed in brain metastatic tissue but had not been observed in primary lung carcinoma. Because there are readily available therapeutic agents for these abnormalities, targeted therapies that are more specific to brain metastases would be beneficial.
|Title of host publication||Brain Metastases from Primary Tumors|
|Subtitle of host publication||Epidemiology, Biology, and Therapy|
|Number of pages||7|
|Publication status||Published - 2015 Jan 8|
Bibliographical notePublisher Copyright:
© 2015 Elsevier Inc. All rights reserved.
All Science Journal Classification (ASJC) codes